United Kingdom
Cannabis-based products for medical use
Thanks to deep scientific expertise, rigorous process management and quality control, EMMAC ensures MHRA medical-grade quality products with the full accreditation of relevant regulatory certifications for its manufacturing, distribution and supply processes.
Cutting-edge research
In partnership with leading European academic institutions including Imperial College London, EMMAC is at the forefront of research to deliver clinical data regarding the efficacy of medical cannabis for pain and the potential health benefits for patients.
End-to-end control
At EMMAC Life Sciences Group, we control the entire lifecycle of our medical cannabis – from cultivation and extraction to production and distribution.
People & expertise
EMMAC’s board and management team comprise of seasoned industry executives and consultants. Every member brings with them a wealth of knowledge and experience – from a range of scientific, medical, technical and FMCG backgrounds.
EMMAC announces pioneering research collaboration with Imperial College London
EMMAC Across Europe
EMMAC has developed unique supply and distribution partnerships across Europe to establish itself not only as a thought leader at the very forefront of research into the medical benefits of cannabis but also a European leader in the production and supply of medical cannabis, hemp and other derivative products.
Press Releases
Curaleaf International launches own range of Medical Cannabis Products in Germany
11 May 2021, London. Curaleaf International (formerly EMMAC Life Sciences Group), Europe’s largest vertically integrated cannabis company, is pleased to
Novel Foods CBD Products Validation from the Foods Standards Agency
27 April 2021, London. Further to the announcement on 26 April 2021 that it received validation from the European Commission
Cannabidiol Novel Foods Validation from the European Commission
26 April 2021, London. EMMAC Life Sciences Group, Europe’s largest vertically integrated cannabis company, is pleased to announce it has
Curaleaf Completes Acquisition of EMMAC and Secures US$130 Million Investment from a Single Strategic Institutional Investor
WAKEFIELD, Mass., April 7, 2021 — Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading
EMMAC Life Sciences Group launches first Medical Cannabis Flower for UK Market
30 March 2021, London. EMMAC Life Sciences Group (‘EMMAC’), Europe’s largest independent cannabis company, is pleased to announce that its
Curaleaf to Enter European Cannabis Market with Acquisition of EMMAC Life Sciences Limited – Europe’s Leading Independent Cannabis Company
EMMAC Brings the Largest Vertically Integrated Independent Cannabis Company in Europe with a Presence in Key European Medical Cannabis Markets,
Stay informed
Fill in the form below to receive the latest news and developments in medical cannabis from EMMAC
